Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects
with relapsed and refractory multiple myeloma.
Patients must have received prior treatment with bortezomib and either thalidomide or
lenalidomide and be refractory to their last treatment.